Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
about
Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolismRoxadustat (FG-4592): Correction of Anemia in Incident Dialysis PatientsComparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.Notch Downregulation and Extramedullary Erythrocytosis in Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 2-Deficient Mice.Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial.HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.Current and future chemical therapies for treating anaemia in chronic kidney disease.Expanding roles of the hypoxia-response network in chronic kidney disease.Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?Hypoxia enhances tenocyte differentiation of adipose-derived mesenchymal stem cells by inducing hypoxia-inducible factor-1α in a co-culture system.Investigational therapies for renal disease-induced anemia.A mechanistic link between renal ischemia and fibrosis.A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat.Emerging drugs for the treatment of kidney disease-induced anemia.Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases.Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.Targeting Hypoxia Signaling for Perioperative Organ Injury.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.Roxadustat in the treatment of anaemia in chronic kidney disease.Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function.Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease.The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney diseaseImpact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease
P2860
Q30251565-A75C53FD-E99E-43AC-BA46-8A07540C683BQ33926530-CDB8015E-5CCA-4A93-BA18-E3A438328BD2Q36746098-71215384-4081-4894-B65E-488FB770C55BQ37173066-BE89DED7-3CB8-4A2D-9F23-BB6BD63C15DFQ37559382-AD67070A-A5A4-4858-AA2A-6F69C5682B1AQ37705646-5B3C1374-33A9-4777-A40D-542373FE3003Q38380236-3229A19D-694E-47BF-819B-D4344ECD1BD7Q38666170-78BEF889-6731-4D4E-9CF6-4A26C3E61695Q38690858-09ECB536-3D29-49A6-9406-A16DD3C97BF1Q38726764-C9AAD7B7-E192-4873-8025-68D464658C63Q38735845-8539EE2F-1D22-42E2-B6AC-651C5CAA3D26Q38740776-788A4674-6D3A-4033-ABF8-8C168F7CBFC1Q38782787-F43D0313-6F6C-4D06-B536-5B8B0DE09A52Q38819455-29AB8FCC-8B23-4A17-8779-DE3D57C42E25Q38903388-70B647FF-30F7-400A-BEF9-A2FEE384620BQ38909908-4FA3EC5C-9339-4343-82DF-59B114FA32F9Q38930912-5269A8C3-09B0-4F85-827D-2A5C109AAAECQ39101277-1D32AF75-F4F1-46F9-A7E4-88B247871B94Q39291945-CC78CF11-E8DE-44F5-8A15-CF79AC3FD7DBQ41161788-1C332482-C45C-4376-A291-BE91F260734BQ41823201-14324FDB-0441-4623-BA55-4735FBAF2019Q46224147-BF33DF7A-B9FE-492A-9346-FB0B7A347A0AQ46258639-CCDFD82A-8119-4243-9E55-52BEB0C9F0C9Q47571628-7E6DA2D0-0B4D-4B1A-9CBA-A3EA0CF0515DQ48140646-7402FD45-BF79-4CDD-982A-D3C4777B8790Q48252464-EDBF3C33-3059-4DF0-8BD5-5900990FD8C8Q48319000-67ADC38E-BCF0-4ED4-AC23-E6314E6A4B1BQ48512043-38ABD2C2-6B2E-4C98-8255-232A7F7158A0Q48563617-EA9E6242-AFD6-4139-8DC4-C3C56F347C87Q49176400-5034CC92-2DD6-4E54-9225-E56382554A7CQ49649941-71D25140-631F-482A-9DAA-4B8CDFAE921FQ53383073-CBBAF489-5C48-476B-A377-BE0482BD6898Q54979172-17E112BB-7430-4BA8-9990-7E6F5F2C653AQ55379461-98D338DB-304D-4B55-81C2-3C1B02B0F9E3Q57073613-969A77EE-0E21-412A-9CD4-EEB85BC34787Q58700150-7C8CF1C0-FFE5-4553-B10B-983DE518C1F4
P2860
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@ast
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@en
type
label
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@ast
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@en
prefLabel
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@ast
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@en
P2093
P2860
P356
P1476
Randomized placebo-controlled ...... ey disease (NDD-CKD) patients.
@en
P2093
Anatole Besarab
Joachim Hertel
Kin-Hung Peony Yu
Raja Zabaneh
Robert Leong
Robert Provenzano
Stefan Hemmerich
Stephen J Klaus
Thomas B Neff
P2860
P304
P356
10.1093/NDT/GFV302
P407
P577
2015-08-03T00:00:00Z